The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma

Abstract Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rathasapa Patarat, Shoji Riku, Pattapon Kunadirek, Natthaya Chuaypen, Pisit Tangkijvanich, Apiwat Mutirangura, Charoenchai Puttipanyalears
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9a12337f182644bfa0b70a760b398123
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a12337f182644bfa0b70a760b398123
record_format	dspace
spelling	oai:doaj.org-article:9a12337f182644bfa0b70a760b3981232021-12-02T16:17:27ZThe expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma10.1038/s41598-021-94330-12045-2322https://doaj.org/article/9a12337f182644bfa0b70a760b3981232021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94330-1https://doaj.org/toc/2045-2322Abstract Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs. Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected. As a result, GSE 49515 and GSE 58208 were found. Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes. We randomized three selected genes (FLNA, CAP1, and CLU) from the significant p-value group (p-values < 0.001). Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected. Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.47 ± 4.43, 28.01 ± 3.75, 29.64 ± 3.90) were lower than healthy group (34.23 ± 3.54, 32.90 ± 4.15, 32.18 ± 5.02) (p-values < 0.0001). The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.8%, 88.0%, 65.8%), CLU (63.4%, 93.3%, 31.3%), CAP1 (67.2%, 83.3%, 39.1%). The tests were performed in two and three gene combinations. Results demonstrated high accuracy of 86.2%, sensitivity of 85% and specificity of 88.4% in the FLNA and CLU combination. Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.9%, sensitivity of 77.6% and specificity of 75%. Also, we founded that our gene combination performs better than the current gold standard for HCC screening. We concluded that FLNA and CLU combination have high potential for being HCC novel markers. Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods.Rathasapa PataratShoji RikuPattapon KunadirekNatthaya ChuaypenPisit TangkijvanichApiwat MutiranguraCharoenchai PuttipanyalearsNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rathasapa Patarat Shoji Riku Pattapon Kunadirek Natthaya Chuaypen Pisit Tangkijvanich Apiwat Mutirangura Charoenchai Puttipanyalears The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
description	Abstract Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs. Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected. As a result, GSE 49515 and GSE 58208 were found. Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes. We randomized three selected genes (FLNA, CAP1, and CLU) from the significant p-value group (p-values < 0.001). Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected. Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.47 ± 4.43, 28.01 ± 3.75, 29.64 ± 3.90) were lower than healthy group (34.23 ± 3.54, 32.90 ± 4.15, 32.18 ± 5.02) (p-values < 0.0001). The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.8%, 88.0%, 65.8%), CLU (63.4%, 93.3%, 31.3%), CAP1 (67.2%, 83.3%, 39.1%). The tests were performed in two and three gene combinations. Results demonstrated high accuracy of 86.2%, sensitivity of 85% and specificity of 88.4% in the FLNA and CLU combination. Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.9%, sensitivity of 77.6% and specificity of 75%. Also, we founded that our gene combination performs better than the current gold standard for HCC screening. We concluded that FLNA and CLU combination have high potential for being HCC novel markers. Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods.
format	article
author	Rathasapa Patarat Shoji Riku Pattapon Kunadirek Natthaya Chuaypen Pisit Tangkijvanich Apiwat Mutirangura Charoenchai Puttipanyalears
author_facet	Rathasapa Patarat Shoji Riku Pattapon Kunadirek Natthaya Chuaypen Pisit Tangkijvanich Apiwat Mutirangura Charoenchai Puttipanyalears
author_sort	Rathasapa Patarat
title	The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_short	The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_full	The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_fullStr	The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_full_unstemmed	The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
title_sort	expression of flna and clu in pbmcs as a novel screening marker for hepatocellular carcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9a12337f182644bfa0b70a760b398123
work_keys_str_mv	AT rathasapapatarat theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT shojiriku theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT pattaponkunadirek theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT natthayachuaypen theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT pisittangkijvanich theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT apiwatmutirangura theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT charoenchaiputtipanyalears theexpressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT rathasapapatarat expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT shojiriku expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT pattaponkunadirek expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT natthayachuaypen expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT pisittangkijvanich expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT apiwatmutirangura expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma AT charoenchaiputtipanyalears expressionofflnaandcluinpbmcsasanovelscreeningmarkerforhepatocellularcarcinoma
_version_	1718384245669363712

The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma

Ejemplares similares